NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
National Cancer Institute, Naples
Qilu Pharmaceutical Co., Ltd.
Asan Medical Center
Asan Medical Center
Dong-A University Hospital
University of Pittsburgh
University of Pittsburgh
Hoffmann-La Roche
SCRI Development Innovations, LLC
University of Michigan Rogel Cancer Center